Pancreatic adenocarcinomas are aggressive and frequently develop resistance to all current therapies. Replication-selective adenoviruses can overcome resistance to chemotherapeutics through their sensitizing effects on drug-induced cell killing. We previously found that adenovirus deleted in the anti-apoptotic E1B19K gene enhanced gemcitabine-induced apoptotis. Here we demonstrate that our engineered double-deleted AdDD mutant (deleted in the pRb-binding E1ACR2 region and E1B19K) selectively replicates and enhances cell killing in combination with DNA-damaging cytotoxic drugs in pancreatic cancer cells. Combinations of AdDD with gemcitabine, irinotecan or cisplatin resulted in two-to fourfold decreases in EC 50 (half maximal effective concentration) values and was more efficent than similar combinations with wild-type virus, the dl1520 (ONYX-015) and dl922-947 mutants. AdDD replication was impaired in normal bronchial human epithelial cells and did not sensitize the cells to drugs. Gemcitabine-insensitive AsPC-1, BxPC-3 and PANC-1 cells were efficiently killed by irinotecan in combination with AdDD. Suboptimal doses of AdDD and gemcitabine significantly prolonged time to tumor progression in two human pancreatic tumor xenograft in vivo models, PT45 and SUIT-2. We conclude that AdDD has low toxicity to normal cells while potently sensitizing pancreatic cancer cells to DNA-damaging drugs, and holds promise as an improved therapeutic strategy for pancreatic cancer.
INTRODUCTION
Pancreatic adenocarcinomas are always aggressive with poor prognosis and few treatment options, and are currently among the leading causes of cancer-related deaths globally with the lowest survival rates. 1 Gemcitabine is currently the treatment of choice but has negligible effects with limited improvements in survival. 2 Late presentation of symptoms, rapid progression and development of resistance to all available therapies contribute to the poor treatment outcomes. Development of improved therapies for this malignancy is therefore a priority.
Replication-selective oncolytic adenoviruses represent a novel approach for the treatment of cancer with promising advantages such as tumor-selective amplification and replication resulting in cancer cell lysis with minimal spread in normal tissue in vivo. [3] [4] [5] [6] [7] The oncolytic mutants most intensively evaluated in the clinic to date are ONYX-015 and H101, both with the E1B55K-gene deleted. 8, 9 These mutants are defective in p53 binding/degradation and nuclear export of viral mRNA, functions that are essential for viral propagation in normal cells. These functions are complemented in the majority of cancers due to the frequent inactivating mutations of p53 and alterations in mRNA export, rendering the mutants tumor selective. 8, 10 Clinical trials with ONYX-015 and H101 proved that administration of oncolytic adenoviruses is safe in humans and H101 is now licensed in China for treatment of head and neck cancers (Oncorine; Shanghai Sunway Biotech). 9 However, extensive evaluation in various human cancers demonstrated that significant antitumor efficacy required combination with cytotoxic drugs such as 5-fluorouracil and cisplatin. [11] [12] [13] [14] [15] The ONYX-015 virus was also evaluated in pancreatic cancer patients, demonstrating that treatment of this malignancy with adenoviral mutants is feasible although efficacy was limited and only observed in combination with gemcitabine. 16, 17 The main reason for the poor efficacy of ONYX-015 is the attenuated viral replication and spread caused by the deletion of the E1B55K gene that severely impairs the viral life cycle. 10, 18 In vivo, the absence of the E3B immuno-modulatory genes has also been suggested to prevent efficient spread of this mutant. 19, 20 More recently, improved oncolytic viruses have been engineered with smaller specific gene deletions to retain viral potency. Several of these mutants target the pRb/p16 pathway by deletion of the small E1ACR2 domain, essential for pRb binding and inactivation, and S-phase entry to support viral replication and propagation. [21] [22] [23] The pRb/p16 pathway is deregulated in the majority of cancers including most pancreatic tumors and consequently replication can proceed in tumor but not in normal cells with intact cell cycle control. 24, 25 The E1ACR2-deleted oncolytic adenoviral mutants have superior efficacy compared with ONYX-015 in numerous in vivo cancer models. 21, 23, 26 However, both higher levels of replication in normal cells and liver toxicity were reported for the E1ACR2-deleted dl922-947 mutant compared with ONYX-015. 21, 27 The first clinical evaluation of an E1ACR2-deleted mutant, adenovirus serotype 5 (Ad5)-D24RGD was recently completed in a phase I trial for recurrent malignant gliomas (http://www.clinicaltrialsfeeds.org/ clinical-trials/show/NCT00805376).
We previously demonstrated that deletion of the viral anti-apoptotic E1B19K gene resulted in mutants that replicated as efficiently as wildtype virus in cancer cells and could be prevented from replicating in normal cells in response to TNF-induced apoptotic signalling. 28, 29 In addition, when E1B19K-deleted mutants were combined with gemcitabine cell killing was greatly enhanced through drug-induced apoptosis. 30 To improve on efficacy and specificity, we generated a doubledeleted mutant (AdDD) by taking advantage of the high-anticancer efficacy of E1ACR2-deleted viruses and the apoptosis promoting function of E1B19K-deleted mutants as well as the retention of the intact E3 region for sustained replication in vivo. 31 While the E1B19K deletion alone is not sufficiently selective for cancer cells, we found that AdDD was highly selective and could significantly enhance cell killing in combination with chemotherapeutics.
Here, we present data demonstrating that AdDD replicates as efficiently as wild-type virus in a panel of pancreatic cancer cell lines. In addition, AdDD was highly defective in normal primary cells correlating with the impaired capacity to induce S phase and had reduced cytotoxicity compared with AdD19K. Importantly, AdDD retained the ability of AdD19K to sensitize cancer cells in combination with cytotoxic drugs to a higher degree than wild type, ONYX-015 and dl922-947 viruses. Coadministration of AdDD and gemcitabine in vivo in mice with human pancreatic xenografts resulted in significant tumor growth reduction at low, non-toxic doses. Notably, the combination of AdDD with irinotecan led to increased cell death in all cell lines, including those that were insensitive to gemcitabine. In light of these results, we propose AdDD as a potent new therapeutic for pancreatic cancers, specifically in combination with DNA-damaging drugs. In addition, the wider spectrum of action for AdDD in combination with irinotecan holds promise for the treatment of gemcitabine-resistant disease.
RESULTS
AdDD replicates as efficiently as wild-type virus in pancreatic cancer cell lines but is severely impaired in normal primary cells To explore the therapeutic potential of AdDD the level of viral replication was explored in a panel of pancreatic cell lines with deregulated pRb and cell cycle pathways (Supplementary Table 1) . In all tested cell lines amplification of the AdDD genome was as efficient as that of wild-type virus (Ad5tg; Figure 1a ). The rate of viral production, including intracellular and released viral particles (v.p.), paralleled the rate of genome amplification (Figure 1b ). To test whether AdDD production was restricted to cancer cells, normal epithelial cells were also infected with AdDD or Ad5tg. We selected the primary normal human bronchial epithelial (NHBE) cells because of the lack of untransformed normal pancreatic or gastrointestinal cells. To mimic the situation in vivo where the majority of cells in healthy tissue do not proliferate, the NHBE cells were growth arrested Figure 2aI ). In cells with higher levels of S phase (o6%; data not shown), Ad5tg replication was also increased (Figure 2aII ). In proliferating NHBE cells (410% cells in S phase; data not shown) higher levels of replication were observed 48 h after infection with the Ad5tg virus at 9.9Â10 3 ±7.3Â10 3 PFU per ml while replication was still severely impaired with AdDD at 33±22 PFU per ml (Po0.01; Figure 2aIII ). The low levels of AdDD production in NHBE cells correlated with the defect in S-phase induction of this mutant ( Figure 2b Figure 1) . In contrast to irinotecan and cisplatin, the response to gemcitabine was not dose-dependent and complete cell killing was never achieved even at the highest dose possible (data not shown). Therefore, the relative sensitivity to gemcitabine was compared at doses killing 30% of cells with PT45 and SUIT-2 the most, and BxPc-3 the least sensitive (Table 1) . Dose responses to AdDD were analyzed with and without the addition of drugs at concentrations killing p30% of cells alone. The highest levels of sensitization and cell killing were obtained when viruses and drugs were administered simultaneously (rather than sequentially; data not shown) and all combination studies were performed under these conditions. In the presence of gemcitabine, enhanced cell killing was observed in SUIT-2, PT45 and MIA PaCa-2 cells (Figures 3a and b , and Supplementary Figure 1A) , with decreasing AdDD EC 50 values from twofold in MIA PaCa to two-to fourfold in PT45 cells (Po0.001). Similar increases in cell killing were observed for gemcitabine in combination with AdD19K, while the effects with Ad5tg, ONYX-015 or dl922-947 were less in SUIT-2 ( Figure 3a ) and PT45 (Supplementary Figure  1A) . In contrast to the enhanced cell killing with AdDD and gemcitabine in MIAPaCa-2 cells, Adtg in combination with gemcitabine caused dose-dependent inhibition of cell killing (Po0.001; Figure 3b ). 
In normal primary cells, cell-killing efficacy of AdDD is not enhanced in combination with cytotoxic drugs
To explore whether the primary NHBE cells were resistant to enhancement of cell killing with AdDD and drugs, viability assays were performed with and without gemcitabine or irinotecan at the same or higher concentrations that efficiently sensitized the cancer cells (Figures 4a-d) . In contrast to cancer cells, we found that in NHBE cells, AdD19K was more cytotoxic than Ad5tg while AdDD had similar cytotoxicity to that of Ad5tg. The NHBE cells were highly insensitive to gemcitabine with only 40% cell death at the highest possible dose at 400 mM (data not shown). However, irinotecan did kill NHBE cells although at a dose 10-fold higher than the corresponding doses in cancer cells (EC 50 825 ± 50 mM). Importantly, when AdDD was combined with the drugs at concentrations that sensitized the cancer cells, gemcitabine at 10 nM and irinotecan at 25 mM, no significant (P40.05) sensitization was detected in NHBE cells (Figure 4b ). Even at a higher dose of gemcitabine at 10 mM no increase in cell death was observed (Figure 4c ), while a slight increase with a 10-fold higher dose of irinotecan at 250 mM was detected (Figure 4d ). These results demonstrate that combinations of low doses of AdDD and DNA-damaging drugs that kill cancer cells do not increase cell killing in the normal primary NHBE cells.
Increased cell death in response to drugs is not due to increased viral replication, but due to increased apoptosis We previously reported that gemcitabine has an inhibitory effect on AdD19K replication and that the increased cell death is a result of increased apoptosis when the two agents are combined. 30 We also observed an increase in caspase 3 activation with AdDD in prostate cancer cells. 31 In agreement with these observations, at early time points both Ad5tg and AdDD genome amplification was attenuated in the presence of gemcitabine, but increased over time and was not significantly lower 72 h post infection (Figures 5a and b ; dashed lines). However, in the presence of irinotecan, amplification of both Ad5tg and AdDD was severely attenuated at all time points, indicating a stronger inhibitory effect on viral replication (Figures 5a and b ; dashed lines). Despite differences in the degree of inhibition, neither gemcitabine nor irinotecan enhances viral replication, and increased replication can thus be excluded as a mechanism for the sensitization.
To investigate the mechanism of cell death in response to AdDD and drugs, we performed combination assays in the presence of the pan-caspase inhibitor zVAD-fmk. Addition of the inhibitor almost completely blocked sensitization in the presence of both gemcitabine and irinotecan (Figures 5c and d) , indicating that the enhanced cell killing is mainly caused by increased apoptosis. The inhibitor did not significantly alter the EC 50 values for AdDD alone (Figures 5c and d) , and did not have any effect on untreated cells at this dose (25 mM; data not shown).
Combining low doses of AdDD and gemcitabine in vivo greatly enhances growth inhibition of pancreatic tumor xenografts The AdDD mutant administered alone in PT45 and SUIT-2 subcutaneous xenograft models in vivo potently inhibited tumor growth in a dose-dependent manner in both models (data not shown). To evaluate the effects of the combined treatments, suboptimal doses of viral mutants and gemcitabine were administered (Figures 6a-c) . In animals with PT45 tumors, time to progression was significantly (Po0.01) prolonged with median survival from 37 days and 82 days for AdDD and gemcitabine (5 mg kg À1 ), respectively, to 153 days for the combination (Figure 6b) . The response to the combination treatment was greater than additive as the low dose of AdDD at 1Â10 6 v.p. had no significant efficacy alone (mock (phosphatebuffered saline) treated; median survival 23 days; Figures 6a and b) . The corresponding single-deleted AdDCR2 mutant also did not cause tumor regression alone at this low dose, but in combination with gemcitabine median survival was prolonged from 41 days to 79 days (Figure 6a and data not shown) that was not significantly different from gemcitabine alone (82 days). On the other hand, the singledeleted AdD19K mutant was highly efficacious, and had prolonged survival in combination with gemcitabine from 71 days for virus alone to 129 days for the combination (Po0.01) as previously demonstrated. 30 Similar results were obtained in the SUIT-2 model with significantly prolonged time to progression when suboptimal doses of AdDD (1Â10 9 v.p.) and gemcitabine (15 mg kg À1 ) were combined; from 25 days for both virus and drug alone to 445 days when combined (Po0.01; Figure 6c ). Despite the difficulties with this model due to tumor ulceration necessitating early termination, the combination treatment resulted in a higher proportion of surviving animals when the study was terminated (45 days; 60%) than a higher dose of gemcitabine at 30 mg kg À1 (no surviving animals; Figure 6c ). 
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Expression of E1A and hexon in tumors was detected with all viruses from 20 days after infection and throughout the study in 30-50% of each section compared with 0% in non-infected groups (shown for AdDD; Figure 6d ). E1A and hexon could be detected as late as 140 days after treatment with both AdDD alone or in combination with gemcitabine in animals with remaining tumor tissue. These findings demonstrate that the two deletions in AdDD rendered the mutant highly efficacious with superior potency in combination with gemcitabine in vivo. In addition, the viral replicative cycle was sustained in the tumors throughout the study suggesting intratumoral spread.
DISCUSSION
Given the dismal prognosis for patients diagnosed with pancreatic cancer, a malignancy with a survival rate that has not improved over the last 40 years, new therapies are urgently needed. Here, we demonstrate that AdDD, a recently developed highly potent and tumor-selective oncolytic adenovirus, is a promising candidate for clinical development. The focus of this study was to determine the efficacy of AdDD in a panel of pancreatic cell lines and to explore interactions of AdDD with chemotherapeutics used in the clinic. We found that pancreatic cancer cells highly insensitive to gemcitabine could be efficiently eliminated with AdDD. When low doses of gemcitabine were combined with AdDD (but not with wild-type virus) more than additive cell killing was observed in gemcitabinesensitive cells. In addition, irinotecan in combination with AdDD enhanced cell killing in all tested pancreatic cancer cell lines independent of the sensitivity to irinotecan or gemcitabine. Potent sensitization to drugs was observed with all mutants with the anti-apoptotic E1B19K gene deleted and to a lesser degree in combination with ONYX-015, deleted in the second viral anti-apoptotic gene E1B55K. We hypothesize that by attenuating the viral anti-apoptotic defense mechanisms, cell killing through drug-induced apoptosis is promoted in pancreatic cancer cells, as previously demonstrated for mutants with only the E1B19K deletion, 30 and also for the AdDD mutant in this study. Notably, the E1B19K deletion attenuates replication and spread, and prevents replication in the presence of TNF in normal cells and tissue, but not in the majority of cancer cells. [28] [29] [30] 35, 36 We recently engineered the adenoviral mutant AdDD to replicate only in cells with disrupted cell cycle regulation by deleting the pRbbinding E1ACR2 region in wild-type Ad5. 31 This deletion restricts replication mainly to cancer cells as demonstrated for E1ACR2-deleted viruses. 21, [37] [38] [39] [40] The additional E1B19K deletion also attenuates viral replication in normal cells through abortive replication in response to extrinsically induced apoptosis. 28, 29, 35, 36 Therefore, the double-deleted AdDD mutant has two viral functions deactivated to prevent amplification in normal tissue while potent replication and spread can proceed in pancreatic tumors that frequently have both deregulated cell cycle and apoptosis pathways. 24, 25, 41 In this study, we demonstrate that the combination of both E1ACR2 and E1B19K deletions confers significant advantages over either deletion alone, especially in combination with DNA-damaging chemotherapeutics. In fact, we show that AdDD has the same capacity as AdD19K, deleted solely in the E1B19K gene, to enhance the sensitization of cancer cells to cytotoxic drugs while tumor selectivity is retained. The deletion of the E1ACR2 domain alone (for example, dl922-947) resulted in less potent sensitization in combination with drugs.
To achieve efficient tumor elimination in situ viral replication must proceed at high levels, a shortcoming of the prototype oncolytic adenovirus ONYX-015 that is severely attenuated in the majority of tumors contributing to its low efficacy in vivo. 3, 4, 6, 10, 11 We demonstrate here that the deletions in AdDD did not affect the viral life cycle in pancreatic cancer cells. AdDD replication was indeed as efficient as that of wild-type Ad5tg, while production was severely impaired in normal NHBE cells. Deregulation and evasion of apoptosis are general alterations in pancreatic cancer, 41 and absence of the anti-apoptotic E1B19K gene is probably not sufficient to trigger apoptosis in response to viral infection allowing for viral replication to proceed. In contrast, in normal cells with intact apoptotic pathways the infected cells are quickly eliminated to prevent viral production and spread. 30 Accordingly, higher cytotoxicity with E1B19K-deleted mutants compared with Ad5tg was seen in normal cells. Higher toxicity in proliferating normal cells was also reported with other replication-selective mutants such as dl922-947 despite the attenuated replication. 21, 37 However, for the dl922-947 virus the toxicity was likely caused by the additional E3B deletion that also has a role in anti-apoptotic functions. 19, 21, 37 Importantly, inclusion of the E1ACR2 deletion in AdDD resulted in lower toxicity to normal cells compared with the single-deleted AdD19K, and was similar to that of wild-type virus, while replication was significantly lower. Even though both AdD19K and AdDD were more potent than ONYX-015, our previous in vivo data using immunocompetent models 31 indicate that these mutants administered alone would not be sufficiently efficacious in eliminating tumors in the clinic despite the presence of intact E3 genes. Therefore, we further investigated whether antitumor efficacy of AdDD could be enhanced by simultaneous treatment of cells with cytotoxic drugs currently used in the clinic for pancreatic cancer.
Many E1A-expressing oncolytic adenoviruses have been demonstrated to interact synergistically with chemotherapeutics to more efficiently eliminate different tumor types and cancer cells. 4, 9, 26, 38, 40, 42, 43 Here, we demonstrate that the potency of AdDD was increased in combination with both gemcitabine and irinotecan. In previous studies we found that AdD19K in PT45 and SUIT-2 cells could enhance gemcitabine-induced apoptosis and that AdDD interacted synergistically with docetaxel in prostate cancer cells. 30, 31 The data in this study demonstrate that the sensitization with AdDD or AdD19K is superior to the earlier developed oncolytic mutants, ONYX-015 and dl922-947, in the pancreatic cancer cells. In addition, we demonstrate that the sensitization is due to increased apoptotic cell death, independent of the DNA-damaging drug used in this study and of their inhibitory effect on viral replication. We hypothesize that deletion of the E1B19K protein is essential to obtain high levels of sensitization in combination with DNA-damaging drugs and that the E1ACR2 deletion does not compromise this effect. Further studies are ongoing to define in more detail the viral components necessary for the sensitization with chemotherapeutic drugs. However, only 50% of the tested pancreatic cell lines could be sensitized by combining AdDD with gemcitabine, whereas all cells were sensitized with irinotecan. We found that the sensitivity of each cell line to gemcitabine alone was predictive of whether sensitization could be achieved. In fact, in the most insensitive AsPC-1 and BxPC-3 cells, gemcitabine had antagonistic effects with Ad5tg but not AdDD. One reason for the antagonism could be that inhibition of DNA replication in response to gemcitabine might also block viral DNA replication as previously observed. 30, 39 Therefore, the higher doses of gemcitabine in the insensitive cells (to adjust to the higher EC 50 values) could cause greater inhibition of viral DNA replication, resulting in loss of the positive interaction between virus and drug. The possibility of antagonism needs careful investigation in future studies when planning combination therapies with oncolytic viruses. Nevertheless, antagonism with AdDD was not observed in any cell line, suggesting that the deletion of E1B19K might push the balance towards cell death. The degree of sensitization with the combination of AdDD and irinotecan, a topoisomerase I inhibitor, 34, 44 was similar to that obtained in combination with gemcitabine in SUIT-2, PT45 and MIA PaCa-2 cells, with two-to fourfold reductions in EC 50 values. In contrast to gemcitabine, the enhancement of cell killing was independent of the sensitivity of each cell line to drug and might reflect the different mechanisms of action for these drugs. In fact, significant sensitization with AdDD and irinotecan was demonstrated both in the most and least drug-sensitive cells, SUIT-2 and AsPC-1, respectively. It was previously reported that a single-deleted E1ACR2-deletion mutant could also enhance the antitumor effect of irinotecan in glioma cells. 40 Treatment of gemcitabine-resistant pancreatic cancers with low doses of irinotecan in combination with AdDD, therefore, seems a promising future option.
Finally, in vivo verification of our findings demonstrated significant tumor growth inhibition and increased time to progression in comparison with either virus or gemcitabine alone at doses that did not have significant effects when administered as single agents. Despite the limitations with our in vivo models of human pancreatic tumor (PT45 and SUIT-2) xenografts in athymic mice, previous studies in immunocompetent animals and observations from clinical trials suggest that the retention of an intact immuno-modulatory E3B region will promote sustained replication in vivo if the oncolytic mutant is highly replication competent in the tumor tissue. 3, 7, 19 Here, we demonstrate that in the PT45 xenografts both early and late viral gene expression was detected as late as 140 days after virus administration, suggesting that productive replication occurred after gemcitabine administration. We propose that the inhibition of tumor growth in vivo is the result of sustained viral replication leading to increased intratumoral spread and promotion of gemcitabine-induced apoptosis in response to infection with AdDD, defective in antiapoptotic functions.
In conclusion, we have demonstrated that AdDD is a potent oncolytic adenovirus in pancreatic cancer cells with greatly attenuated replication and spread in normal primary cells, and that the interaction with DNA-damaging drugs can greatly improve tumor efficacy while selectivity is retained. Furthermore, the combination of AdDD with the less commonly clinically used drug irinotecan had broader efficacy in all tested pancreatic cancer cells. These results hold promise for the treatment of pancreatic cancer and we propose that clinical trials should follow.
MATERIALS AND METHODS

Cell lines and viruses
The pancreatic adenocarcinoma cell lines MIA PaCa-2, PANC-1, BxPC-3, AsPC-1 (ATCC-LGC, Teddington, UK), SUIT-2 and PT45 (Cell Services, Cancer Research UK, London, UK) were grown under standard conditions in Dulbecco's modified eagle media (PAA, Yeovil, UK) supplemented with 10% fetal calf serum (PAA). All cell lines were authenticated by STR profiling throughout the study (Cell Services, Cancer Research UK) and verified to be identical to the profiles reported by ATCC or to the original vials obtained from collaborators (SUIT-2; Professor T Iwamura, Miyazaki, Japan and PT45; Professor H Kalthoff, Kiel, Germany). NHBE cells were cultured according to the manufacturer's instructions (Lonza, Cambridge, UK). Growth-arrested NHBE cells were obtained by seeding cells at high densities (420 000 cm À2 ) and kept at confluence for X5 days before treatment. Growth arrest was assessed by staining of cells with BrdU (see below).
All viruses, but ONYX-015, were derived from Ad5 as previously described: 30, 31 Ad5tg (wild-type), AdD19K (E1B19K-deleted), AdDD (E1ACR2-and E1B19K-deleted), AdDCR2 (E1ACR2-deleted), dl312 (E1A-and E3B-deleted) and dl922-947 (E1ACR2-and E3B-deleted). ONYX-015 (E1B55K-and E3B-deleted) is an Ad2/5 chimera. Viruses were generated and characterized as previously described 19, 31 with ratios of v.p. to plaque-forming units (PFU) at 3-30 v.p. per PFU. In all assays, cells were infected 24 h after seeding for 2 h at 100 particles per cell (p.p.c.) in serum-free media, unless otherwise stated.
Quantitative PCR
For quantification of viral genome amplification, DNA was isolated from attached cells with the QIamp Blood Mini Kit according to the manufacturer's instructions (Qiagen, Crawley, UK). Specific primers for the viral E2A gene were designed using the Primer Express software (Applied Biosystems, Carlsbad, CA, USA); forward (5¢-GGATACAGCGCCTGCATAAAAG-3¢) and reverse (5¢-CC AATCAGTTTTCCGGCAAGT-3¢). The human GAPDH gene was used as internal standard in all reactions with the following primers; forward (5¢-TGGGC TACACTGAGCACCAG-3¢) and reverse (5¢-GGGTGTCGCTGTTGAAGTCA-3¢). Amplified DNA was detected by SYBR Green on a 7500 Real Time PCR System (Applied Biosystems) and viral genome levels were analyzed by the DDCt method as described previously. 45 For each experimental condition samples were prepared in parallel for analysis of viral uptake, 4 h after infection, to monitor equal level of infectivity.
Viral replication assay
Cells and media were collected at the indicated time points, freeze-thawed, and analyzed by the limiting dilution method (TCID 50 ) on JH293 cells. 19 Internal controls of known activity were included in every assay.
BrdU incorporation and cell cycle analysis
For analysis of cell cycle progression cells were incubated with 10 mM BrdU for 1 h at 371C, trypsinized, washed in phosphate-buffered saline, fixed in 70% EtOH at 4 1C for X24 h and denatured in 2N HCl. Staining was with the monoclonal anti-BrdU antibody (1:50; Becton Dickinson, Oxford, UK), followed by FITC-conjugated anti-mouse antibody (1:50; DAKO, Ely, UK). Cells were resuspended in phosphate-buffered saline containing RNAse (100 mg ml À1 ; Sigma, Gillingham, UK) and propidium iodide (50 mg ml À1 ; Invitrogen, Paisley, UK). Flow cytometry was on a FACScalibur instrument (Becton Dickinson) acquiring 20 000 events per sample and data were analyzed using the FlowJo software 8.8.6 (Tree Star Inc., Ashland, OR, USA).
Cell viability assay
Cell killing assays were performed as described previously. 30 Cells were infected with viruses and/or treated with gemcitabine (Gemzar; Eli Lilly, Indianapolis, IN, USA), irinotecan (Campto, Hospira UK Limited, Leamington Spa, UK), cisplatin (Faulding Pharmaceuticals Plc, Leamington Spa, UK) or the pancaspase inhibitor zVAD-fmk (Calbiochem, San Diego, CA, USA) 24 h after seeding, and assayed 3 days later using the 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium assay (Promega, Southampton, UK) to quantify live cells as an indirect measurement of cell death. Dose-response curves were generated to determine the concentration of each agent killing 50% of cells (EC 50 ) using untreated cells or cells treated with one agent only as controls. Each data point was generated from triplicate samples and experiments repeated at least three times.
In vivo tumor growth inhibition
Tumors were grown in one flank of C57BL athymic mice (ICRF nu/nu) by subcutaneous implantation of the human pancreatic cancer PT45 and SUIT-2 cells, at 5Â10 6 cells per flank and 1Â10 6 cells per flank, respectively. Dose responses to viral mutants or gemcitabine were determined by administration of virus intratumorally at 1Â10 6 -10 10 v.p. per injection on days 1, 3 and 5, and gemcitabine at 5.0-30.0 mg kg À1 intraperitoneally on days 2 and 8 after virus injection. To determine efficacy in response to combination treatments, suboptimal doses of each agent were administered. Control groups were mock treated with either phosphate-buffered saline or the non-replicating dl312 mutant. Tumor volumes were determined double-blinded by a third party at least twice weekly: volume¼(lengthÂwidth 2 Âp)/6. Treatments were initiated when tumors were 100±20 ml with tumor growth and progression followed until tumors reached 1.44 cm 2 (PT45) and/or symptomatic tumor ulceration occurred (SUIT-2; according to UK Home Office Regulations). Survival analysis was performed according to the method of Kaplan-Meier (log-rank test for statistical significance) including each animal until its tumor endpoint volume was reached and reported as time to tumor progression, X600 or X450 ml for PT45 and SUIT-2, respectively. Tumor growth curves were compared using one-way analysis of variance for significance, and were stopped when the first animal in each group reached the tumor size end point.
Viral gene expression in vivo
Following treatments of PT45 xenografts, tumors were harvested 10-160 days after the last virus administration and snap frozen in liquid nitrogen (nX3 per group). Tumors were processed for immunohistochemistry of E1A and hexon expression, and counterstained with hematoxylin and eosin as described previously. 19, 30 Supplementary Information accompanies the paper on Gene Therapy website (http://www.nature.com/gt)
